Warby Parker Inc.
Our Company Warby Parker is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. Every day, our team of over 4,000 employees is focused on our mission to inspire and impact the world with vision, purpose, and style (without charging a premium for it).
$25.67
+$0.04 (+0.16%)
EOD Oct 22, 2026
The business is unprofitable at the operating level (-0.61% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 13.0% YoY with margins expanding 3.3pp.
At 428x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
427.8x earnings, 148.4x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$912M
▲ +13.0% YoY
Net Income (TTM)
$8M
▲ +108.0% YoY
Op. Margin
0.17%
▲ +3.3pp YoY
ROIC
0.20%
▲ +3.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$22M
▲ +26.0% YoY
Op. Cash Flow (TTM)
$95M
▲ +12.2% YoY
Net Debt
-$42M
Net Cash Position
Cash & Equiv.
$293M
5Y CAGR: +17.2%
5Y CAGR: +28.1%
Continue Research
SourceComputed from the 10-Q filed 6 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 22 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Warby Parker (WRBY) overvalued?
At a P/E of 427.8 and a price-to-free-cash-flow of 148.4, Warby Parker (WRBY) trades above a two-stage DCF intrinsic value of about $9.06 per share, so at $25.67 the stock looks overvalued (64.7% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Warby Parker scores 65/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Warby Parker's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $9.06 per share for WRBY, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $6.80. At today's $25.67, that puts the stock about 64.7% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Warby Parker a high-quality business?+
Warby Parker scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 0.2% operating margin and a 0.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Warby Parker a good stock to buy right now?+
That depends on valuation and quality together, not either alone. WRBY currently trades above its estimated intrinsic value and scores 65/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Ophthalmic Goods
Spot a number that looks wrong? Check it in WRBY's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing WRBY
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.